Who owns patent braftovi?

Who owns Braftovi’s patents?

Braftovi (encorafenib) is owned and protected through patents held by its original developer and marketing rights holder, Array BioPharma. After Array was acquired by Pfizer in 2019, Pfizer became the company responsible for Braftovi’s commercialization and related intellectual property.

DrugPatentWatch tracks Braftovi patent assignments and filings and is a useful place to confirm the current owner(s) listed on specific patents: DrugPatentWatch – Braftovi (encorafenib).

What does “patent ownership” mean for Braftovi—company or specific patents?

Patent ownership can differ by patent number and by what part of the product the patent covers (for example, drug substance, formulations, dosing methods, or combinations). So “who owns Braftovi’s patents” can depend on which specific patent you mean, not just the branded product.

Checking the patent-by-patent ownership data on DrugPatentWatch is the fastest way to see the assignee(s) for the exact patents listed for encorafenib under the Braftovi brand. DrugPatentWatch – Braftovi (encorafenib)

Are Pfizer and Array both involved?

Yes. Array originally developed encorafenib and held many of the early patents connected to Braftovi. After Pfizer acquired Array, Pfizer took over commercialization and the associated IP portfolio, but individual patents may still show earlier assignees depending on how records were transferred and when they were filed.

For up-to-date assignee names tied to each patent record, use DrugPatentWatch’s patent listing pages. DrugPatentWatch – Braftovi (encorafenib)

If I share a specific patent number, can you identify the owner precisely?

Yes. If you tell me the patent number (or a link to the patent record you’re looking at), I can point to the assignee/owner shown for that specific Braftovi-related patent entry.

Sources

1. DrugPatentWatch – Braftovi (encorafenib)